Court Denies Bayer’s Request to Block J&J’s Prostate Cancer Drug Marketing

A federal judge in Manhattan has ruled against Bayer’s request for a preliminary injunction to halt Johnson & Johnson’s marketing of its prostate cancer drug Erleada, dealing a significant blow to Bayer in the ongoing legal battle between the pharmaceutical giants.

The dispute centers on J&J’s promotional claim that Erleada reduces the risk of death by 51% compared to competing treatments, including Bayer’s drug Nubeqa. Bayer contends this claim is misleading because it relies on retrospective real-world evidence rather than randomized clinical trials, which are considered the gold standard in medical research.

Judge Dale Ho of the U.S. District Court for the Southern District of New York determined that Bayer failed to demonstrate a likelihood of success on the merits of its false advertising claims under the Lanham Act, which prohibits misleading advertising that could harm competitors or confuse consumers.

In his ruling, Judge Ho emphasized that the limitations of J&J’s study were properly disclosed alongside the results, weakening Bayer’s argument that healthcare providers and patients were being misled. The court characterized the dispute as more of a scientific disagreement about interpreting observational data rather than a clear case of improper promotion.

“The record did not demonstrate errors serious enough to render the company’s statements materially false,” the judge noted in his decision.

The ruling comes at a critical time for both companies as they compete in the lucrative market for androgen receptor inhibitors used to treat prostate cancer, a disease that claims approximately 35,000 lives annually in the United States.

Bayer has expressed its intention to continue pursuing the case, describing the denial of the preliminary injunction as coming at a “very early stage” in the legal proceedings.

“The company maintains that J&J’s superiority claims are false, misapply real-world evidence, mislead prescribers and patients, and are intended to increase its market share in a concentrated and increasingly competitive prostate cancer treatment market,” a Bayer spokesperson stated.

J&J, meanwhile, celebrated the ruling as “a win for scientific exchange and a strong win for patients,” adding that the decision “validated the robust methodology of Johnson & Johnson’s scientific rigor and real-world analysis of ERLEADA and its impact on patient outcomes.”

During the court proceedings, Bayer’s legal team, led by attorney Lynn Neuner of Simpson Thacher & Bartlett, argued that J&J’s study contained fundamental flaws including selection bias and non-comparable patient groups. Bayer claimed the study disproportionately reflected off-label use of Nubeqa while Erleada was prescribed on-label, and that the Erleada cohort was significantly larger.

Another concern raised by Bayer was the modern information ecosystem, where AI tools like ChatGPT might surface J&J’s claims to patients researching treatment options. “So 40% of the time my dad’s not making it with Nubeqa?” Neuner rhetorically asked, suggesting that patients might draw dangerous conclusions from what Bayer considers flawed data.

J&J’s attorneys countered that Bayer itself has conducted and promoted studies using real-world evidence in the past. They argued that disputes over scientific methodologies belong in scientific forums rather than courtrooms, warning that judicial intervention could threaten free speech rights.

For Bayer, the stakes are particularly high as Nubeqa represents its flagship product and highest-revenue generator. Had the preliminary injunction been granted, Bayer sought to have J&J issue a court-approved corrective press release to address what Bayer considered misleading marketing materials.

Legal experts note that this case highlights the ongoing tension between pharmaceutical marketing practices and scientific evidence standards. The court’s decision suggests a reluctance to intervene in what it views as legitimate scientific debate between competitors rather than clear-cut deception.

As the case proceeds to trial, the pharmaceutical industry will be watching closely to see how the court ultimately rules on the permissible boundaries of marketing claims based on real-world evidence versus randomized clinical trials, potentially setting a precedent for future advertising disputes in the healthcare sector.